The following Evaluation reports have been archived and are no longer available as downloads from this website. If you would like to have access to any of the documents listed please contact Prescribing Support.
<< Return to the list of current Evaluation Reports
| Document | Published |
|---|---|
| Adefovir dipivoxil in chronic hepatitis B infection (N) | Jun 04 |
| Alemtuzumab in chronic lymphocytic leukaemia | Mar 07 |
| An update on newer agents for the treatment of pulmonary hypertension | Mar 04 |
| Aromatase inhibitors in early stage breast cancer (N) | Mar 07 |
| Bevacizumab in metastatic breast cancer (N) | Sep 07 |
| Bortezomib second-line in multiple myeloma (N) | Mar 06 |
| Docetaxel or paclitaxel in early stage breast cancer (N) | Mar 06 |
| Drotrecogin alfa (activated) in severe sepsis (N) | Dec02 |
| Entecavir in chronic hepatitis B (N) | Apr 07 |
| Erlotinib in non-small cell lung cancer | Mar 06 |
| Ibandronic acid in hypercalcaemia of malignancy, bone pain and the prevention of skeletal events associated with skeletal metastases | Aug 05 |
| Ibritumomab in b-cell follicular non-hodgkin’s lymphoma | Mar 06 |
| Natalizumab in multiple sclerosis (N) | Mar 07 |
| Omalizumab in severe persistent allergic asthma (N) | Jun 06 |
| Palonosetron for the prevention of nausea and vomiting associated with cancer chemotherapy | Mar 07 |
| Pegvisomant in acromegaly | Jan 06 |
| Pemetrexed in malignant pleural mesothelioma (N) | Mar 06 |
| Rituximab in combination with cvp chemotherapy for the management of follicular non-hodgkin’s lymphoma | Mar 06 |
| Teriparatide in osteoporosis (N) | Jul 04 |
